ZA958647B - Aroyl-piperidine derivatives - Google Patents

Aroyl-piperidine derivatives

Info

Publication number
ZA958647B
ZA958647B ZA958647A ZA958647A ZA958647B ZA 958647 B ZA958647 B ZA 958647B ZA 958647 A ZA958647 A ZA 958647A ZA 958647 A ZA958647 A ZA 958647A ZA 958647 B ZA958647 B ZA 958647B
Authority
ZA
South Africa
Prior art keywords
aroyl
piperidine derivatives
substd
opt
halo
Prior art date
Application number
ZA958647A
Other languages
English (en)
Inventor
Silvio Ofner
Siem Jacob Veenstra
Walter Schilling
Original Assignee
Ciba Geigy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy filed Critical Ciba Geigy
Publication of ZA958647B publication Critical patent/ZA958647B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Insulating Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Suspension Of Electric Lines Or Cables (AREA)
ZA958647A 1994-10-14 1995-10-13 Aroyl-piperidine derivatives ZA958647B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH309194 1994-10-14

Publications (1)

Publication Number Publication Date
ZA958647B true ZA958647B (en) 1996-04-15

Family

ID=4248427

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA958647A ZA958647B (en) 1994-10-14 1995-10-13 Aroyl-piperidine derivatives

Country Status (23)

Country Link
US (1) US5965562A (xx)
EP (1) EP0707006B1 (xx)
JP (1) JP3022951B2 (xx)
KR (1) KR100413985B1 (xx)
CN (1) CN1066445C (xx)
AT (1) ATE178602T1 (xx)
AU (1) AU705851B2 (xx)
CA (1) CA2160444C (xx)
DE (1) DE59505575D1 (xx)
DK (1) DK0707006T3 (xx)
ES (1) ES2132580T3 (xx)
FI (1) FI114795B (xx)
GR (1) GR3030515T3 (xx)
HU (1) HUT74103A (xx)
IL (1) IL115572A (xx)
MX (1) MX9504349A (xx)
MY (1) MY114679A (xx)
NO (1) NO308034B1 (xx)
NZ (1) NZ280212A (xx)
RU (1) RU2158731C2 (xx)
SA (1) SA96160637B1 (xx)
TW (1) TW397825B (xx)
ZA (1) ZA958647B (xx)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW397825B (en) * 1994-10-14 2000-07-11 Novartis Ag Aroyl-piperidine derivatives
RU2156250C2 (ru) * 1995-04-24 2000-09-20 Новартис Аг Производные хромона, способ их получения и фармацевтическая композиция
WO1997045119A1 (en) * 1996-05-24 1997-12-04 Novartis Ag Use of substance p antagonists for treating social phobia
AR018376A1 (es) 1998-05-26 2001-11-14 Novartis Ag Composiciones farmaceuticas que se pueden dispersar de una manera espontanea y el uso de las mismas para la manufactura de un medicamento
CA2339628C (en) * 1998-08-25 2008-06-03 Novartis Ag Use of substance p antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia and use of nk-1 receptor antagonists for the treatment of chronic fatigue syndrome
US6777428B1 (en) 1999-02-10 2004-08-17 Eli Lilly And Company 5-HT1f agonist
AU781179B2 (en) 1999-11-03 2005-05-12 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
JP2001294582A (ja) * 2000-04-12 2001-10-23 Fuji Chemical Industries Ltd 光学活性アミノブチロラクトンの製造法
US7084152B2 (en) 2000-07-11 2006-08-01 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines therapeutic use thereof
GB0220953D0 (en) 2002-09-10 2002-10-23 Novartis Ag Organic compounds
GB2394417A (en) * 2002-10-24 2004-04-28 Novartis Ag Solid dispersion comprising a piperidine substance P antagonist and a carrier
AU2004232799A1 (en) 2003-04-18 2004-11-04 Eli Lilly And Company (Piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-HT1F agonists
EP1778639B1 (en) 2004-07-15 2015-09-02 Albany Molecular Research, Inc. Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
KR20080044840A (ko) 2005-07-15 2008-05-21 에이엠알 테크놀로지, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기위한 용도
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
AU2008204380B2 (en) 2007-01-10 2013-08-15 Msd Italia S.R.L. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
EP2170076B1 (en) 2007-06-27 2016-05-18 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
CN102638982B (zh) 2009-05-12 2015-07-08 百时美施贵宝公司 (S)-7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉的晶型及其用途
MX2011011901A (es) 2009-05-12 2012-01-20 Albany Molecular Res Inc Tetrahidroisoquinolinas aril, heteroaril, y heterociclo sustituidas y uso de las mismas.
KR101830447B1 (ko) 2009-05-12 2018-02-20 알바니 몰레큘라 리써치, 인크. 7-(［1,2,4］트리아졸로［1,5-α］피리딘-6-일)-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로이소퀴놀린 및 이의 용도
MX2012004377A (es) 2009-10-14 2012-06-01 Merck Sharp & Dohme Piperidinas sustituidas que aumentan la actividad de p53 y sus usos.
EP3330377A1 (en) 2010-08-02 2018-06-06 Sirna Therapeutics, Inc. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
EP2606134B1 (en) 2010-08-17 2019-04-10 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
ES2663009T3 (es) 2010-10-29 2018-04-10 Sirna Therapeutics, Inc. Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
CN103732592A (zh) 2011-04-21 2014-04-16 默沙东公司 胰岛素样生长因子-1受体抑制剂
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
RU2660429C2 (ru) 2012-09-28 2018-07-06 Мерк Шарп И Доум Корп. Новые соединения, которые являются ингибиторами erk
JP6290237B2 (ja) 2012-11-28 2018-03-07 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 癌を処置するための組成物および方法
AR094116A1 (es) 2012-12-20 2015-07-08 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de hdm2
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
CN111808017B (zh) * 2020-08-05 2023-11-28 国家纳米科学中心 一种含氮杂环化合物及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
US5145967A (en) * 1989-04-20 1992-09-08 Anaquest, Inc. Method for preparing 4-alkoxyalkyl-4-phenylaminopiperdines and derivatives thereof
IE903957A1 (en) * 1989-11-06 1991-05-08 Sanofi Sa Aromatic amine compounds, their method of preparation and¹pharmaceutical compositions in which they are present
FR2654725B1 (fr) * 1989-11-23 1992-02-14 Rhone Poulenc Sante Nouveaux derives de l'isoindolone, leur preparation et les compositions pharmaceutiques qui les contiennent.
US5126455A (en) * 1989-12-13 1992-06-30 Glaxo Inc. Preparation of substituted alkali metal piperidine-4-carboxylates
PL168236B1 (pl) * 1990-05-31 1996-01-31 Pfizer Sposób wytwarzania podstawionych piperydyn PL PL PL
EP0532527B1 (en) * 1990-06-01 1994-11-09 Pfizer Inc. 3-amino-2-aryl quinuclidines, process for their preparation and pharmaceutical compositions containing them
JPH0772175B2 (ja) * 1990-09-28 1995-08-02 フアイザー・インコーポレイテツド 窒素含有非芳香族複素環の縮合環類似体
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
TW397825B (en) * 1994-10-14 2000-07-11 Novartis Ag Aroyl-piperidine derivatives

Also Published As

Publication number Publication date
CA2160444C (en) 2006-11-28
DE59505575D1 (de) 1999-05-12
TW397825B (en) 2000-07-11
US5965562A (en) 1999-10-12
FI954829A (fi) 1996-04-15
KR960014121A (ko) 1996-05-22
RU2158731C2 (ru) 2000-11-10
EP0707006B1 (de) 1999-04-07
IL115572A (en) 2001-05-20
HU9502973D0 (en) 1995-12-28
ATE178602T1 (de) 1999-04-15
AU705851B2 (en) 1999-06-03
CA2160444A1 (en) 1996-04-15
NO954067L (no) 1996-04-15
AU3317495A (en) 1996-04-26
FI114795B (fi) 2004-12-31
DK0707006T3 (da) 1999-10-18
KR100413985B1 (ko) 2004-03-26
ES2132580T3 (es) 1999-08-16
FI954829A0 (fi) 1995-10-11
JPH08176145A (ja) 1996-07-09
EP0707006A1 (de) 1996-04-17
CN1133839A (zh) 1996-10-23
NO954067D0 (no) 1995-10-13
MY114679A (en) 2002-12-31
NZ280212A (en) 2001-10-26
NO308034B1 (no) 2000-07-10
SA96160637B1 (ar) 2005-06-14
CN1066445C (zh) 2001-05-30
IL115572A0 (en) 1996-01-19
GR3030515T3 (en) 1999-10-29
JP3022951B2 (ja) 2000-03-21
HUT74103A (en) 1996-11-28
MX9504349A (es) 1997-03-29

Similar Documents

Publication Publication Date Title
GR3030515T3 (en) Aroyl-piperidine derivatives
DE3879264D1 (de) N-substituierte azole.
DE59509777D1 (de) Tricyclische Pyrazol-Derivate
DE3683175D1 (de) Azolylmethyloxirane - ihre herstellung und verwendung als pflanzenschutzmittel.
NO20033765D0 (no) 4-Fenylpiperidinforbindelser
DE69701923D1 (de) 3-(Piperid-4-yl)-1,2-benzisoxazol- und 3-(Piperazin-4-yl)-1,2-benzisoxazol-Derivate als Antipsychotika
MY132009A (en) Pharmaceutical compounds.
ES2121183T3 (es) Ligandos selectivos de los receptores 5ht1d-5ht1b derivados de indol-piperacina utiles como medicamentos.
MX9701949A (es) Derivados de distamicina substituidos con bis-(2-haloetil) aminofenilo como agentes antitumorales y antivirales.
FI834730A0 (fi) 1-karboxialkanoylperhydro-indol-2-karboxylsyror och deras derivat
DE59507220D1 (de) Verwendung von 1,2-überbrückten 1,4-Dihydropyridinen als selektive Kaliumkanalmodulatoren
NO304314B1 (no) Cykloheksanderivater og anvendelse av forbindelsene for fremstilling av legemidler
DE3867563D1 (en) 2-amino-5-hydroxy-4-pyrimidone.
ES2090901T3 (es) Composiciones de tincion de fibras queratinicas a base de 4-monoindolil-1,2-naftoquinonas y nuevos compuestos de 4-monoindolil-1,2-naftoquinonas.
ECSP951529A (es) Compuestos farmaceuticos
DE59002904D1 (de) Cyclopropanthiocarbonsaeureamide.
DE60239284D1 (de) Azotierte tetrahydropyridyl-alkyl-heterozyklen mit tnf-wirkung